APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Regorafenib

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Regorafenib Market Outlook and Growth Opportunities 2026

Report ID 174032080423 December 2025198 pages

Choose your research edition.

Industry ResearchRegorafenib Industry Research Report 2026113 pages · $2,950 USDIndustry Growth & TrendsGlobal Regorafenib Industry Growth and Trends Forecast to 203278 pages · $3,450 USDMarket StructureGlobal Regorafenib Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032174 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Regorafenib Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Regorafenib Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Regorafenib market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Regorafenib is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Regorafenib is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Regorafenib is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Regorafenib market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Regorafenib market include Beacon Pharmaceuticals, Bayer Pharmaceuticals and Drug International, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Regorafenib market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Regorafenib and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Regorafenib sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Regorafenib market size, projected growth trends, production technologies, key applications, and end-use industries.

Regorafenib Segment by Company

Beacon Pharmaceuticals

Bayer Pharmaceuticals

Drug International

Regorafenib Segment by Type

Bottled Packaging

Film Coated Packaging

Regorafenib Segment by Application

Advanced Hepatocellular Carcinoma

Advanced Gastrointestinal Stromal Tumours

Metastatic Colorectal Cancer

Others

Regorafenib Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Regorafenib status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Regorafenib market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Regorafenib significant trends, drivers, influence factors in global and regions.

6. To analyze Regorafenib competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Regorafenib market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Regorafenib and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Regorafenib.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Regorafenib market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Regorafenib industry.

Chapter 3: Detailed analysis of Regorafenib manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Regorafenib in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Regorafenib in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Regorafenib Industry Trends Table 2. Regorafenib Industry Drivers Table 3. Regorafenib Industry Opportunities and Challenges Table 4. Regorafenib Industry Restraints Table 5. Global Regorafenib Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Regorafenib Revenue Share by Company (2021-2026) Table 7. Global Regorafenib Sales Volume by Company (k pcs) & (2021-2026) Table 8. Global Regorafenib Sales Volume Share by Company (2021-2026) Table 9. Global Regorafenib Average Price (US$/pcs) of Company (2021-2026) Table 10. Global Regorafenib Company Ranking, (2024-2026) & (USD Million) Table 11. Global Regorafenib Key Company Manufacturing Base & Headquarters Table 12. Global Regorafenib Company, Product Type & Application Table 13. Global Regorafenib Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Regorafenib by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Bottled Packaging Table 18. Significant Companies of Film Coated Packaging Table 19. Global Regorafenib Sales Volume by Type 2021 VS 2025 VS 2032 (k pcs) Table 20. Global Regorafenib Sales Volume by Type (2021-2026) & (k pcs) Table 21. Global Regorafenib Sales Volume by Type (2027-2032) & (k pcs) Table 22. Global Regorafenib Sales Volume Share by Type (2021-2026) Table 23. Global Regorafenib Sales Volume Share by Type (2027-2032) Table 24. Global Regorafenib Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Regorafenib Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Regorafenib Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Regorafenib Sales Value Share by Type (2021-2026) Table 28. Global Regorafenib Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Advanced Hepatocellular Carcinoma Table 30. Significant Companies of Advanced Gastrointestinal Stromal Tumours Table 31. Significant Companies of Metastatic Colorectal Cancer Table 32. Significant Companies of Others Table 33. Global Regorafenib Sales Volume by Application 2021 VS 2025 VS 2032 (k pcs) Table 34. Global Regorafenib Sales Volume by Application (2021-2026) & (k pcs) Table 35. Global Regorafenib Sales Volume by Application (2027-2032) & (k pcs) Table 36. Global Regorafenib Sales Volume Share by Application (2021-2026) Table 37. Global Regorafenib Sales Volume Share by Application (2027-2032) Table 38. Global Regorafenib Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Regorafenib Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Regorafenib Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Regorafenib Sales Value Share by Application (2021-2026) Table 42. Global Regorafenib Sales Value Share by Application (2027-2032) Table 43. Global Regorafenib Sales by Region: 2021 VS 2025 VS 2032 (k pcs) Table 44. Global Regorafenib Sales by Region (2021-2026) & (k pcs) Table 45. Global Regorafenib Sales Market Share by Region (2021-2026) Table 46. Global Regorafenib Sales by Region (2027-2032) & (k pcs) Table 47. Global Regorafenib Sales Market Share by Region (2027-2032) Table 48. Global Regorafenib Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Regorafenib Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Regorafenib Sales Value Share by Region (2021-2026) Table 51. Global Regorafenib Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Regorafenib Sales Value Share by Region (2027-2032) Table 53. Global Regorafenib Market Average Price (US$/pcs) by Region (2021-2026) Table 54. Global Regorafenib Market Average Price (US$/pcs) by Region (2027-2032) Table 55. Global Regorafenib Sales by Country: 2021 VS 2025 VS 2032 (k pcs) Table 56. Global Regorafenib Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Regorafenib Sales by Country (2021-2026) & (k pcs) Table 58. Global Regorafenib Sales Market Share by Country (2021-2026) Table 59. Global Regorafenib Sales by Country (2027-2032) & (k pcs) Table 60. Global Regorafenib Sales Market Share by Country (2027-2032) Table 61. Global Regorafenib Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Regorafenib Sales Value Market Share by Country (2021-2026) Table 63. Global Regorafenib Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Regorafenib Sales Value Market Share by Country (2027-2032) Table 65. Beacon Pharmaceuticals Company Information Table 66. Beacon Pharmaceuticals Business Overview Table 67. Beacon Pharmaceuticals Regorafenib Sales (k pcs), Value (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 68. Beacon Pharmaceuticals Regorafenib Product Portfolio Table 69. Beacon Pharmaceuticals Recent Development Table 70. Bayer Pharmaceuticals Company Information Table 71. Bayer Pharmaceuticals Business Overview Table 72. Bayer Pharmaceuticals Regorafenib Sales (k pcs), Value (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 73. Bayer Pharmaceuticals Regorafenib Product Portfolio Table 74. Bayer Pharmaceuticals Recent Development Table 75. Drug International Company Information Table 76. Drug International Business Overview Table 77. Drug International Regorafenib Sales (k pcs), Value (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 78. Drug International Regorafenib Product Portfolio Table 79. Drug International Recent Development Table 80. Key Raw Materials Table 81. Raw Materials Key Suppliers Table 82. Regorafenib Distributors List Table 83. Regorafenib Customers List Table 84. Research Programs/Design for This Report Table 85. Authors List of This Report Table 86. Secondary Sources Table 87. Primary Sources List of Figures Figure 1. Regorafenib Product Image Figure 2. Global Regorafenib Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Regorafenib Sales Value (2021-2032) & (US$ Million) Figure 4. Global Regorafenib Sales (2021-2032) & (k pcs) Figure 5. Global Regorafenib Sales Average Price (US$/pcs) & (2021-2032) Figure 6. Global Regorafenib Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Bottled Packaging Image Figure 10. Film Coated Packaging Image Figure 11. Global Regorafenib Sales Volume by Type (2021 VS 2025 VS 2032) & (k pcs) Figure 12. Global Regorafenib Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Regorafenib Sales Volume Share by Type (2021-2032) Figure 14. Global Regorafenib Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Regorafenib Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Regorafenib Sales Value Share by Type (2021-2032) Figure 17. Advanced Hepatocellular Carcinoma Image Figure 18. Advanced Gastrointestinal Stromal Tumours Image Figure 19. Metastatic Colorectal Cancer Image Figure 20. Others Image Figure 21. Global Regorafenib Sales Volume by Application (2021 VS 2025 VS 2032) & (k pcs) Figure 22. Global Regorafenib Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Regorafenib Sales Volume Share by Application (2021-2032) Figure 24. Global Regorafenib Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Regorafenib Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Regorafenib Sales Value Share by Application (2021-2032) Figure 27. Global Regorafenib Sales by Region: 2021 VS 2025 VS 2032 (k pcs) Figure 28. Global Regorafenib Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Regorafenib Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Regorafenib Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Regorafenib Sales Value (2021-2032) & (US$ Million) Figure 32. North America Regorafenib Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Regorafenib Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Regorafenib Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Regorafenib Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Regorafenib Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Regorafenib Sales Value (2021-2032) & (US$ Million) Figure 38. South America Regorafenib Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Regorafenib Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Regorafenib Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Regorafenib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Regorafenib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Regorafenib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Regorafenib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Regorafenib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Regorafenib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Regorafenib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Regorafenib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Regorafenib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Regorafenib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Regorafenib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Regorafenib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Regorafenib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Regorafenib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Regorafenib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Regorafenib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Regorafenib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Regorafenib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Regorafenib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Regorafenib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Regorafenib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Regorafenib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Regorafenib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Regorafenib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Regorafenib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Regorafenib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Regorafenib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Regorafenib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Regorafenib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Regorafenib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Regorafenib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Regorafenib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Regorafenib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Regorafenib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Regorafenib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Regorafenib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Regorafenib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Regorafenib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Regorafenib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Regorafenib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Regorafenib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Regorafenib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Regorafenib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Regorafenib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Regorafenib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Regorafenib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Regorafenib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Regorafenib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Regorafenib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Regorafenib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Regorafenib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Regorafenib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Regorafenib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Regorafenib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Regorafenib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Regorafenib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Regorafenib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Regorafenib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Regorafenib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Regorafenib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Regorafenib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Regorafenib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Regorafenib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Regorafenib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Regorafenib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Regorafenib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Regorafenib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Regorafenib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Regorafenib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Regorafenib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Regorafenib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Regorafenib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Regorafenib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Regorafenib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Regorafenib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Regorafenib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Regorafenib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Regorafenib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Regorafenib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Regorafenib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Regorafenib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Regorafenib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Regorafenib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Regorafenib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Regorafenib Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Regorafenib Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • Bottled Packaging
  • Film Coated Packaging
Applications
  • Advanced Hepatocellular Carcinoma
  • Advanced Gastrointestinal Stromal Tumours
  • Metastatic Colorectal Cancer
  • Others
Companies covered
  • Beacon Pharmaceuticals
  • Bayer Pharmaceuticals
  • Drug International

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Regorafenib Sales Value (2021-2032)
  4. 1.2.2 Global Regorafenib Sales Volume (2021-2032)
  5. 1.2.3 Global Regorafenib Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Regorafenib Market Dynamics
  1. 2.1 Regorafenib Industry Trends
  2. 2.2 Regorafenib Industry Drivers
  3. 2.3 Regorafenib Industry Opportunities and Challenges
  4. 2.4 Regorafenib Industry Restraints
3 Regorafenib Market by Company
  1. 3.1 Global Regorafenib Company Revenue Ranking in 2025
  2. 3.2 Global Regorafenib Revenue by Company (2021-2026)
  3. 3.3 Global Regorafenib Sales Volume by Company (2021-2026)
  4. 3.4 Global Regorafenib Average Price by Company (2021-2026)
  5. 3.5 Global Regorafenib Company Ranking (2024-2026)
  6. 3.6 Global Regorafenib Company Manufacturing Base and Headquarters
  7. 3.7 Global Regorafenib Company Product Type and Application
  8. 3.8 Global Regorafenib Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Regorafenib Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Regorafenib Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Regorafenib Market by Type
  1. 4.1 Regorafenib Type Introduction
  2. 4.1.1 Bottled Packaging
  3. 4.1.2 Film Coated Packaging
  4. 4.2 Global Regorafenib Sales Volume by Type
  5. 4.2.1 Global Regorafenib Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Regorafenib Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Regorafenib Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Regorafenib Sales Value by Type
  9. 4.3.1 Global Regorafenib Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Regorafenib Sales Value by Type (2021-2032)
  11. 4.3.3 Global Regorafenib Sales Value Share by Type (2021-2032)
5 Regorafenib Market by Application
  1. 5.1 Regorafenib Application Introduction
  2. 5.1.1 Advanced Hepatocellular Carcinoma
  3. 5.1.2 Advanced Gastrointestinal Stromal Tumours
  4. 5.1.3 Metastatic Colorectal Cancer
  5. 5.1.4 Others
  6. 5.2 Global Regorafenib Sales Volume by Application
  7. 5.2.1 Global Regorafenib Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Regorafenib Sales Volume by Application (2021-2032)
  9. 5.2.3 Global Regorafenib Sales Volume Share by Application (2021-2032)
  10. 5.3 Global Regorafenib Sales Value by Application
  11. 5.3.1 Global Regorafenib Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Regorafenib Sales Value by Application (2021-2032)
  13. 5.3.3 Global Regorafenib Sales Value Share by Application (2021-2032)
6 Regorafenib Regional Sales and Value Analysis
  1. 6.1 Global Regorafenib Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Regorafenib Sales by Region (2021-2032)
  3. 6.2.1 Global Regorafenib Sales by Region: 2021-2026
  4. 6.2.2 Global Regorafenib Sales by Region (2027-2032)
  5. 6.3 Global Regorafenib Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Regorafenib Sales Value by Region (2021-2032)
  7. 6.4.1 Global Regorafenib Sales Value by Region: 2021-2026
  8. 6.4.2 Global Regorafenib Sales Value by Region (2027-2032)
  9. 6.5 Global Regorafenib Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Regorafenib Sales Value (2021-2032)
  12. 6.6.2 North America Regorafenib Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Regorafenib Sales Value (2021-2032)
  15. 6.7.2 Europe Regorafenib Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Regorafenib Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Regorafenib Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Regorafenib Sales Value (2021-2032)
  21. 6.9.2 South America Regorafenib Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Regorafenib Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Regorafenib Sales Value Share by Country, 2025 VS 2032
7 Regorafenib Country-level Sales and Value Analysis
  1. 7.1 Global Regorafenib Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Regorafenib Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Regorafenib Sales by Country (2021-2032)
  4. 7.3.1 Global Regorafenib Sales by Country (2021-2026)
  5. 7.3.2 Global Regorafenib Sales by Country (2027-2032)
  6. 7.4 Global Regorafenib Sales Value by Country (2021-2032)
  7. 7.4.1 Global Regorafenib Sales Value by Country (2021-2026)
  8. 7.4.2 Global Regorafenib Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Regorafenib Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Regorafenib Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Regorafenib Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Regorafenib Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Regorafenib Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Regorafenib Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Regorafenib Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Regorafenib Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Regorafenib Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Regorafenib Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Regorafenib Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Regorafenib Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Regorafenib Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Regorafenib Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Regorafenib Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Regorafenib Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Regorafenib Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Regorafenib Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Regorafenib Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Regorafenib Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Regorafenib Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Regorafenib Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Regorafenib Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Regorafenib Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Regorafenib Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Regorafenib Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Regorafenib Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Regorafenib Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Regorafenib Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Regorafenib Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Regorafenib Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Regorafenib Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Regorafenib Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Regorafenib Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Regorafenib Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Regorafenib Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Regorafenib Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Regorafenib Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Regorafenib Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Regorafenib Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Regorafenib Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Regorafenib Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Regorafenib Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Regorafenib Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Regorafenib Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Regorafenib Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Regorafenib Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Regorafenib Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Regorafenib Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Regorafenib Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Regorafenib Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Regorafenib Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Regorafenib Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Regorafenib Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Regorafenib Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Regorafenib Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Regorafenib Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Regorafenib Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Regorafenib Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Regorafenib Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Regorafenib Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Regorafenib Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Regorafenib Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Regorafenib Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Regorafenib Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Regorafenib Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Regorafenib Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Regorafenib Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Regorafenib Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Regorafenib Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Regorafenib Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Regorafenib Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Regorafenib Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Regorafenib Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Regorafenib Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Regorafenib Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Regorafenib Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Regorafenib Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Regorafenib Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Regorafenib Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Regorafenib Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Regorafenib Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Regorafenib Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Regorafenib Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Beacon Pharmaceuticals
  2. 8.1.1 Beacon Pharmaceuticals Company Information
  3. 8.1.2 Beacon Pharmaceuticals Business Overview
  4. 8.1.3 Beacon Pharmaceuticals Regorafenib Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Beacon Pharmaceuticals Regorafenib Product Portfolio
  6. 8.1.5 Beacon Pharmaceuticals Recent Developments
  7. 8.2 Bayer Pharmaceuticals
  8. 8.2.1 Bayer Pharmaceuticals Company Information
  9. 8.2.2 Bayer Pharmaceuticals Business Overview
  10. 8.2.3 Bayer Pharmaceuticals Regorafenib Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Bayer Pharmaceuticals Regorafenib Product Portfolio
  12. 8.2.5 Bayer Pharmaceuticals Recent Developments
  13. 8.3 Drug International
  14. 8.3.1 Drug International Company Information
  15. 8.3.2 Drug International Business Overview
  16. 8.3.3 Drug International Regorafenib Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Drug International Regorafenib Product Portfolio
  18. 8.3.5 Drug International Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Regorafenib Value Chain Analysis
  2. 9.1.1 Regorafenib Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Regorafenib Sales Mode & Process
  6. 9.2 Regorafenib Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Regorafenib Distributors
  9. 9.2.3 Regorafenib Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst